Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

764 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer.
Guerin M, Gonçalves A, Toiron Y, Baudelet E, Pophillat M, Granjeaud S, Fourquet P, Jacot W, Tarpin C, Sabatier R, Agavnian E, Finetti P, Adelaide J, Birnbaum D, Ginestier C, Charafe-Jauffret E, Viens P, Bertucci F, Borg JP, Camoin L. Guerin M, et al. Oncotarget. 2018 Sep 18;9(73):33762-33777. doi: 10.18632/oncotarget.26031. eCollection 2018 Sep 18. Oncotarget. 2018. PMID: 30333908 Free PMC article.
How may targeted proteomics complement genomic data in breast cancer?
Guerin M, Gonçalves A, Toiron Y, Baudelet E, Audebert S, Boyer JB, Borg JP, Camoin L. Guerin M, et al. Expert Rev Proteomics. 2017 Jan;14(1):43-54. doi: 10.1080/14789450.2017.1256776. Epub 2016 Nov 15. Expert Rev Proteomics. 2017. PMID: 27813428 Review.
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
Guerin M, Rezai K, Isambert N, Campone M, Autret A, Pakradouni J, Provansal M, Camerlo J, Sabatier R, Bertucci F, Charafe-Jauffret E, Hervieu A, Extra JM, Viens P, Lokiec F, Boher JM, Gonçalves A. Guerin M, et al. Eur J Cancer. 2017 Nov;86:28-36. doi: 10.1016/j.ejca.2017.08.025. Epub 2017 Sep 23. Eur J Cancer. 2017. PMID: 28950146 Clinical Trial.
Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.
Pasero C, Gravis G, Guerin M, Granjeaud S, Thomassin-Piana J, Rocchi P, Paciencia-Gros M, Poizat F, Bentobji M, Azario-Cheillan F, Walz J, Salem N, Brunelle S, Moretta A, Olive D. Pasero C, et al. Among authors: guerin m. Cancer Res. 2016 Apr 15;76(8):2153-65. doi: 10.1158/0008-5472.CAN-15-1965. Epub 2016 Apr 5. Cancer Res. 2016. PMID: 27197252
Metastatic hormone sensitive prostate cancer: local treatment strategies.
Walz J, Pignot G, Fakhfakh S, Campagna J, Guerin M, Vicier C, Brunelle S, Salem N, Gravis G. Walz J, et al. Among authors: guerin m. World J Urol. 2021 Feb;39(2):327-337. doi: 10.1007/s00345-020-03296-8. Epub 2020 Jun 25. World J Urol. 2021. PMID: 32588203 Review.
764 results